Lipids & metabolic liver disease
The prognostic value of metabolic dysfunction‐associated steatotic liver disease in acute myocardial infarction: A propensity score‐matched analysis
Main finding · Long-term all-cause mortalityResult — go to the resultHazard ratio 1.330 95% CI 1.106–1.598Authors' conclusion
MASLD embodies a higher burden of metabolic dysfunction and is an independent predictor of long-term mortality in the AMI population. Its early identification may be beneficial for risk stratification and provide therapeutic targets for secondary preventive strategies in AMI.
Study context
- Population
- Patients presenting with acute myocardial infarction at a tertiary centre in Singaporepropensity score-matched
- Participants
- 4,446 patients
- Exposure
- MASLD vs no MASLD in patients presenting with acute myocardial infarction (AMI)
- MASLDn = 2,223
- Outcome
- Long-term all-cause mortality
- Follow-up
- Mean 3.4 ± 2.4 years
Methodological detailspropensity-score matched (age and sex), single-centre (tertiary centre, Singapore)
- Propensity-score matched (age and sex)
- Single-centre (tertiary centre, Singapore)
Main finding
As reported in the abstract
long-term
Hazard ratio
1.330
95% CI 1.106–1.598
P = 0.002
By group
MASLDvs No MASLD
HR 1.330 (95% CI 1.106–1.598); P = 0.002
Observational data: associations, not effects.
Further findings
30-day all-cause mortality
P < 0.001
Baseline characteristics
- MASLD had higher rates of obesity, diabetes and CKD than counterparts
Original publication
The prognostic value of metabolic dysfunction‐associated steatotic liver disease in acute myocardial infarction: A propensity score‐matched analysis. Diabetes Obes Metab. Published 23 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →